Boston Life Sciences, Inc., Appoints Joseph R. Bianchine, M.D., Ph.D., F.A.C.P., F.A.C.C.P., to Scientific Advisory Board

BOSTON--(BUSINESS WIRE)--May 3, 2005--Boston Life Sciences, Inc. (NASDAQ: BLSI) (the "Company"), announced that Joseph R. Bianchine, M.D., Ph.D., F.A.C.P., F.A.C.C.P., has been appointed to the Company's Scientific Advisory Board. Dr. Bianchine brings extensive experience in medicine and clinical pharmacology to BLSI. A former President of the American Society of Clinical Pharmacology and Therapeutics, Dr. Bianchine has been involved with the approval of 15 New Drug Applications.

"Dr. Bianchine strengthens our organization in two ways. First, he brings broad, complimentary clinical pharmacology and product development skills to all of our programs. Second, his in-depth knowledge in Parkinson's disease and stroke will benefit the clinical development of ALTROPANE® and Inosine, as well as the pre-clinical development of our Parkinson's therapeutic, O-1369," said Mark Pykett, President and Chief Operating Officer of BLSI.

A Senior Scientific Advisor for Schwarz Pharma AG, Dr. Bianchine is also currently a Fellow of the American College of Physicians and the American College of Clinical Pharmacology, a Diplomat of the American Board of Clinical Pharmacology and a member of the Editorial Board for the Journal of Clinical Pharmacology, a position he has held for the past 23 years. Dr. Bianchine’s experience spans both industry and academia: he has held senior positions at Pharmacia & Upjohn, Farmitalia-Carlo Erba and Hoffman LaRoche, as well as faculty positions at Ohio State University College of Medicine, Texas Tech University (Lubbock) and Johns Hopkins University College of Medicine. Dr. Bianchine has authored over 300 scientific articles and book chapters in the area of clinical pharmacology and founded the Parkinson’s Disease Research Institute at Texas Tech. He received his doctorate in Pharmacology at Albany Medical College and his M.D. from State University of New York (Syracuse).

"I am pleased to join the Scientific Advisory Board of Boston Life Sciences," stated Dr. Bianchine. "The Company’s CNS product candidates could address serious medical conditions that are presently poorly met. The fundamental science which has been licensed from Harvard, Children's Hospital of Boston and other collaborating institutions is sound. I am looking forward to working with the Company’s team of highly regarded clinicians, researchers, and investigators."

About Boston Life Sciences

Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE® is in Phase III for the diagnosis of Parkinsonian Syndromes (PS) and Phase II for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The Company’s research and pre-clinical CNS programs include Inosine for the treatment of stroke and O-1369 for the treatment of Parkinson’s disease. BLSI’s current research collaborations include Harvard Medical School, Children’s Hospital of Boston and the University of Massachusetts-Worcester.

Statements in this press release regarding Boston Life Sciences’ future financial performance including statements regarding results of operations and net loss, and any other statements about management’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Boston Life Sciences’ actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including those factors contained in Boston Life Sciences’ Annual Report on Form 10-K filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Boston Life Sciences from time to time with the Securities and Exchange Commission. Forward-looking statements include statements regarding Boston Life Sciences’ expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “should”, “will” and “would” or similar words. Boston Life Sciences assumes no obligations to update the information in this press release.

CONTACT: Boston Life Sciences, Inc.
Joseph Hernon, 617-425-0200
jhernon@bostonlifesciences.com
SOURCE: Boston Life Sciences, Inc.